氯吡格雷对基于CYP2C19分型的健康人血浆eNOS和NO水平影响的研究（英文）

被引：3

作者：

张银妆

莫珍珍

戴玮

石珂

陈碧莲

机构：

[1] 中南大学湘雅医院老年病科和老年医学研究中心

来源：

中国临床药理学与治疗学 | 2016年 / 21卷 / 03期

关键词：

氯吡格雷; eNOS; NO; ADMA; CYP2C19基因型;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

1002 ; 100201 ;

摘要：

目的:临床研究显示氯吡格雷可以改善不同CYP2C19基因型健康受试者以及冠心病患者的血管内皮功能,故本研究探讨氯吡格雷的内皮功能保护机制。方法:6名基因型为CYP2C19*1/*1和6名基因型为CYP2C19*2/*2 or*2/*3的健康受试者纳入本实验。所有健康受试者均于空腹12 h后单次服用负荷剂量氯吡格雷300 mg。服药前(0 h)及服药后4 h、24 h静脉采血,检测受试者血浆e NOS、NO、ADMA浓度和血清hs CRP浓度。结果:口服负荷剂量氯吡格雷300 mg 4 h及24 h后,CYP2C19*1/*1组及CYP2C19*2/*2 or*2/*3组血浆e NOS浓度均显著上升,且两组间e NOS浓度差异无统计学意义。同时,CYP2C19*1/*1和CYP2C19*2/*2 or*2/*3组血浆NO水平在口服氯吡格雷4 h、24 h后均显著降低,且两组间NO水平差异无统计学意义。氯吡格雷对两组CYP2C19基因健康受试者血浆(清)ADMA、hs CRP浓度无显著影响。结论:本研究首次证实单负荷剂量氯吡格雷(300 mg)提高中国健康受试者血浆e NOS浓度并伴随血浆NO水平降低,包括基因型是CYP2C19*1/*1和CYP2C19*2/*2 or*2/*3。

引用

页码：298 / 305

页数：8

共 22 条

[1] 吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响 [J].

何春玲 ;

邢文 ;

鲁柯兵 ;

夏礼斌 ;

王安才 .

中国临床药理学与治疗学, 2013, 18 (02) :198-201

[2]

Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats[J]. Sheng DENG, Pan-yue DENG, Jun-lin JIANG, Feng YE, Jing YU, Tian-lun YANG2, Han-wuDENG, Yuan-jian LI3 Department of Pharmacology, Schoolof Pharmaceutical Science, Central South University, Changsha 410078, China;2Department of Cardiovascular Medicine, Xiang-ya Hospital, CentralSouth University, Changsha 410008, China.Acta Pharmacologica Sinica. 2004(12)

[3]

Non‐antiplatelet effect of clopidogrel: improving endothelial function in C hinese healthy subjects with different CYP 2C19 genotype[J] . Yin‐Zhuang Zhang,Bi‐Lian Chen,Wei Zhang,Xin Cao.Clin Exp Pharmacol Physiol . 2015 (1)

[4]

A new mechanism of action of thienopyridine antiplatelet drugs – A role for gastric nitrosthiol metabolism?[J] . R.A. Anderson,S. Bundhoo,P.E. James.Atherosclerosis . 2014 (1)

[5]

Clopidogrel Improves Microvascular Endothelial Function in Subjects with Stable Coronary Artery Disease[J] . Scott R. Willoughby,Lee-Jen Luu,James D. Cameron,Adam J. Nelson,Carlee D. Schultz,Stephen G. Worthley,Matthew I. Worthley.Heart, Lung and Circulation . 2014

[6]

Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?[J] . Luc Rochette,Julie Lorin,Marianne Zeller,Jean-Claude Guilland,Luc Lorgis,Yves Cottin,Catherine Vergely.Pharmacology and Therapeutics . 2013 (3)

[7]

Nitric oxide synthase uncoupling: A therapeutic target in cardiovascular diseases[J] . Nathan D. Roe,Jun Ren.Vascular Pharmacology . 2012 (5-6)

[8] Direct Vasoactive Properties of Thienopyridine-Derived Nitrosothiols [J].

Bundhoo, Shantu S. ;

Anderson, Richard A. ;

Sagan, Ewelina ;

Dada, Jessica ;

Harris, Rebeca ;

Halcox, Julian P. ;

Lang, Derek ;

James, Philip E. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2011, 58 (05) :550-558

[9]

Direct formation of thienopyridine-derived nitrosothiols — Just add nitrite![J] . Shantu S. Bundhoo,Richard A. Anderson,Ewelina Sagan,Nurudeen Hassan,Andrew G. Pinder,Stephen C. Rogers,Keith Morris,Philip E. James.European Journal of Pharmacology . 2011 (2)

[10]

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation[J] . Giuseppe Patti,Domenico Grieco,Giordano Dicuonzo,Vincenzo Pasceri,Annunziata Nusca,Germano Di Sciascio.Journal of the American College of Cardiology . 2011 (7)

← 1 2 3 →